Form 4: Vigil Neuroscience Director Koenig Receives Repriced Stock Options

Director Gerhard Koenig receives repriced stock options from Vigil Neuroscience, Inc. as part of the 2021 Stock Option and Incentive Plan.

Summary

• Gerhard Koenig, a director of Vigil Neuroscience, Inc., received repriced stock option awards on May 3, 2024.
• The repricing was approved by the Issuer's Board of Directors and is effective as of May 3, 2024.
• The exercise price of one stock option award was changed to $3.03 per share, representing the fair market value on the effective date.
• Koenig received multiple stock option awards with different vesting schedules and expiration dates.
• The stock option awards are issued under the 2021 Stock Option and Incentive Plan and the Non-Employee Director Compensation Policy.
• Some of the stock option awards are fully vested and exercisable as of the date of the transaction.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation adjustment. The repricing suggests the stock price may have underperformed, but the action itself is a standard practice to maintain director incentives.

Positives

• The repricing of stock options could incentivize the director to improve company performance.
• The director receives stock options in lieu of cash compensation, aligning their interests with shareholders.
• Some of the stock option awards are fully vested, providing immediate value to the director.

Risks

• The repriced stock option award will revert to its original exercise price if exercised during the Retention Period, which could disincentivize the director from exercising the options in the short term.
• The value of the stock options is dependent on the future performance of the company's stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants and repricings are common practices in the biotechnology industry to incentivize executives and directors, especially in companies with volatile stock prices. This helps align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Repricing of stock options is not uncommon when a company's stock price has declined significantly, as it helps to restore the incentive value of the options.
• Companies like Amgen, Biogen, and Gilead Sciences also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• Shareholders may view the repricing as a positive step to retain and incentivize key personnel.
• The director benefits from the repriced stock options, potentially increasing their alignment with shareholder interests.

Key Dates